Ftse Mib
38.545,35
0,57%
DAX
22.844,50
0,21%
S&P 500
6.115,05
0,01%
NASDAQ
19.987,30
-0,20%
Bitcoin
94.015,78
-1,84%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Legend Biotech Corporation (LEGN) Legend Biotech Corporation (LEGN) Notizie

LEGN

Legend Biotech (LEGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LEGN
DataOraFonteTitoloSimboloCompagnia
22/01/202513:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
10/01/202521:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
19/12/202414:01GlobeNewswire Inc.Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
10/12/202401:35GlobeNewswire Inc.CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
14/11/202414:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEGNLegend Biotech Corporation
12/11/202413:00GlobeNewswire Inc.Legend Biotech Reports Third Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
07/11/202413:30GlobeNewswire Inc.Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LEGNLegend Biotech Corporation
05/11/202415:10GlobeNewswire Inc.Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/202413:30GlobeNewswire Inc.Legend Biotech Appoints Alan Bash as President of CARVYKTI®NASDAQ:LEGNLegend Biotech Corporation
24/10/202414:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Third Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
03/10/202413:30GlobeNewswire Inc.Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaNASDAQ:LEGNLegend Biotech Corporation
27/09/202422:35GlobeNewswire Inc.CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineNASDAQ:LEGNLegend Biotech Corporation
20/08/202414:00GlobeNewswire Inc.Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
09/08/202413:00GlobeNewswire Inc.Legend Biotech Reports Second Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
09/08/202411:50IH Market NewsUS Futures Climb Following Thursday’s Rally, Oil Prices SteadyNASDAQ:LEGNLegend Biotech Corporation
08/08/202422:05GlobeNewswire Inc.Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of DirectorsNASDAQ:LEGNLegend Biotech Corporation
26/07/202413:00GlobeNewswire Inc.Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024NASDAQ:LEGNLegend Biotech Corporation
10/07/202414:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Second Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
02/07/202414:00GlobeNewswire Inc.Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
03/06/202422:00Business WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
29/05/202414:00Business WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
23/05/202423:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
13/05/202413:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202413:00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
22/04/202419:05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202414:00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
06/04/202405:30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202413:30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
15/03/202420:15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202412:00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LEGN

La tua Cronologia

BOV
BLAU3T
Blau Farmaceutica
BIT
P1M388
BNP Paribas Issuance
EU
SFTRY
AMUNDI SMART FACTORY UCI...
NASDAQ
IGF
iShares Global Infrastru...
LSE
0Q41
Europejskie Centrum Odsz...
TSX
5867
Es Networks
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci